Bio-Matrix Scientific Group Inc., a biotech research and development company, recently made a joint announcement with its subsidiary Entest BioMedical Inc. (ENTB.OB), a testing center for various diseases, that they have reached a definitive agreement with Therinject LLC for the development of a immune-therapeutic cancer vaccine.
The companies will first focus on the veterinary market, treating animals with tumors. Itâ€™s a market that Bio-Matrix chairman and CEO David Koos says is a significant one. The company anticipates treating thousands of animals, generating millions in revenues.
â€œCancer is the No. 1 cause of death among dogs. Itâ€™s estimated that one out of every three dogs will get cancer. We anticipate this immuno-therapeutic cancer vaccine could have an efficacy rate of as high as 60 percent where 15 percent to 20 percent is the current cure rate,â€ Koos stated in the press release. â€œWe believe that during the first year this immuno-therapeutic vaccine is available we will treat roughly 2,000 animals resulting in $3,000 revenue per animal or $6 million in first year revenue from veterinary medical applications. The Company anticipates a market niche over the subsequent five years of 40,000 animals being treated. This is before we expand to human clinical trials.â€
Bio-Matrixâ€™s various storage facilities will be used for further research and development of immune-therapeutic treatments for cancer, with a long-term goal utilizing data and technology in support of human clinical trials.
Therinjectâ€™s Chief Scientific Officer Steven Josephs Ph.D. explained immune-therapy, expected efficacy rates, and the treatmentâ€™s affect on the body.
â€œFor many cancers, efficacy rates should be much higher than currently available therapies. Immuno-therapy stimulates the bodyâ€™s own immune system to engage in the treatment process. The development of an anti-cancer immune response would be very effective in dealing with metastatic tumors especially in cases where surgery would no longer be feasible.â€
As per the agreement, Therinject will work collaboratively with Entest BioMedicalâ€™s team to develop intellectual property in this area of cancer treatment, with the ultimate goal of obtaining patents applied by Entest BioMedicalâ€™s.